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ABSTRACT Inﬂammation is thought to underlie the
pathogenesis of many chronic diseases. It is now estab-
lished that obesity results in a state of chronic low-grade
inﬂammation thought to contribute to several meta-
bolic disorders, including insulin resistance and pancre-
atic islet dysfunction. The protein kinases JNK1 and
IKK have been found to serve as critical molecular
links between obesity, metabolic inﬂammation, and
disorders of glucose homeostasis. The precise mecha-
nisms of these linkages are still being investigated.
However, as we discuss here, JNK1 and IKK are
activated by almost all forms of metabolic stress that
have been implicated in insulin resistance or islet
dysfunction. Furthermore, both JNK1 and IKK are
critically involved in the promotion of diet-induced
obesity, metabolic inﬂammation, insulin resistance, and
-cell dysfunction. Understanding the molecular mech-
anisms by which JNK1 and IKK mediate obesity-
induced metabolic stress is likely to be of importance
for the development of new treatments for a variety of
obesity-associated diseases.—Solinas, G., Karin, M.
JNK1 and IKK: molecular links between obesity and
metabolic dysfunction. FASEB J. 24, 000–000 (2010).
www.fasebj.org
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Chronic inflammation is believed to be a key patho-
genic mechanism underlying diseases such as rheumatoid
arthritis, Crohn’s disease, and atherosclerosis, as well as
cancers of the liver, stomach, and colon (1). It is now well
established that obesity is associated with a state of
chronic low-grade inﬂammation (metabolic inﬂam-
mation) that is a major player in the pathogenesis of
several metabolic disorders including type 2 diabetes
and the so-called metabolic syndrome (2, 3). The
stress-activated protein kinases JNK1 and IKK are
central signal transducers in innate immunity and
stress responses that control the expression of several
proinﬂammatory genes. The JNK subgroup of stress-
activated kinases, comprising the JNK1-3 isoforms
and various splicing variants, belongs to the mitogen-
activated protein kinases (MAPK) family, whose con-
stituents are activated in response to growth factors,
proinﬂammatory cytokines, microbial components
such as lipopolysaccharide (LPS), and a variety of
stresses (4, 5). Once activated, the JNKs phosphory-
late and activate transcription factors including
TCF/Elk-1, ATF2, and c-Jun, leading to increased Jun
and Fos gene transcription and increased AP-1 tran-
scription factor activity (4, 5). The JNKs have also
been implicated in post-transcriptional control of
gene expression by causing stabilization of inherently
unstable mRNAs encoding cytokines and other in-
ﬂammatory mediators (6, 7) (Fig. 1A). IKK, on the
other hand, is one of the 2 catalytic subunits (to-
gether with IKK) of the IkB kinase (IKK) complex,
whose activity is rapidly stimulated by proinﬂamma-
tory cytokines, viral and microbial components, and
numerous other inducers (8) (Fig. 1B). IKK is re-
sponsible for activation of the NF-kB/Rel family of
transcription factors through its ability to phosphor-
ylate their IkB inhibitors and target them to prote-
olitic degradation (8). Once freed from the IkB
grasp, NF-kB dimers enter the nucleus and regulate
transcription of genes involved in innate immunity
and inﬂammation, as well as the maintenance of cell
survival and tissue homeostasis (9) (Fig. 1B). Gener-
ally speaking the JNKs and the IKK complex are
situated at the focal points of different signaling
pathways involved in innate immunity, inﬂammation,
and stress, whose main function is to activate host
defense and maintain homeostasis (4, 8, 10).
Recently it has become evident that interference with
either JNK1 or IKK activity improves insulin signaling in
mouse models of obesity and lipid-induced glucose intol-
erance (11, 12). Because almost all metabolic stressors
that cause insulin resistance or islet dysfunction activate
JNK1 and/or IKK (see Fig. 3, 4), these protein kinases
occupy key roles in linking obesity to insulin resistance,
type 2 diabetes, and the metabolic syndrome and are
therefore the focus of this review.
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OBESITY AND TYPE-2 DIABETES ARE
CHARACTERIZED BY CHRONIC LOW-GRADE
METABOLIC INFLAMMATION
The ﬁrst evidence for a pathogenic role of inﬂamma-
tion in type 2 diabetes is dated to more than a
century ago when it was shown that the anti-inﬂam-
matory drug salicylate has beneﬁcial effects on dia-
betic patients (13, 14). The “metabolic inﬂamma-
tion” hypothesis was revived and gained new
popularity with the demonstration that interference
with the proinﬂammatory cytokine TNF- protects
from obesity-induced insulin resistance in rodent
models (15, 16). In addition to TNF-, other proin-
ﬂammatory cytokines, such as IL-6 and IL-1, are
induced during obesity and were shown to cause
insulin resistance in some models (17, 18). However,
the role of IL-6 in the pathogenesis of insulin resis-
tance in humans has been challenged (19, 20).
Consistent with a role for innate immunity and
inﬂammation in obesity-induced insulin resistance, it
was reported that mice bearing a mutation in the gene
encoding Toll-like receptor 4 (TLR4), the sensor for
bacterial LPS and other agonists, show improved insu-
lin sensitivity in a model of free fatty acid (FFA)-
induced insulin resistance (21). A hallmark of obesity-
induced inﬂammation is macrophage inﬁltration into
adipose tissue (22, 23). In obesity, adipose tissue mac-
rophages (ATMs) are polarized toward the inﬂamma-
tory M1 phenotype and express the CD11c marker, and
most of them are localized around necrotic adipocytes
or next to the residual lipid droplet left behind a dead
adipocyte and form typical crown-like structures (CLSs)
(24–26) (Fig. 2A). Macrophages are believed to play an
important role in obesity-induced insulin resistance by
sensing lipid accumulation or cell damage and produc-
ing cytokines and other mediators that interfere with
insulin signaling (2). The importance of macrophages
and hematopoietic cells in general is supported by
several studies in mice bearing speciﬁc genetic muta-
tions in hematopoietic cells (generated by bone mar-
row transplantation) or in myeloid cells (obtained by
conditional Cre-Lox recombination). Such studies have
shown that disruption of the Ikk gene in myeloid cells
or the Jnk1 locus in hematopoietic cells reduces meta-
bolic inﬂammation and improves insulin sensitivity in
models of diet-induced obesity (27–29). Genetic dele-
tion of fatty acid binding protein FABP (30) or Cbl-
associated protein CAP (31) within hematopoietic cells
also reduces metabolic inﬂammation and improves
insulin sensitivity, whereas mice with a conditional
ablation of the Ppar gene in macrophages show in-
creased susceptibility to obesity-induced inﬂammation
and insulin resistance (32, 33). The latter is due to loss
of the anti-inﬂammatory action of PPAR (32, 33). It
was also shown that recruiting macrophages to adipose
tissue by overexpression of the chemokine MCP-1 in
adipose tissue of lean mice is sufﬁcient to induce
insulin resistance (34). Conversely, depletion of CD11c-
positive myeloid cells by injection of diphtheria toxin in
mice overexpressing the diphtheria toxin receptor un-
der the control of the CD11c promoter restores insulin
sensitivity in obese insulin-resistant mice (35).
How hematopoietic cells induce insulin resistance
and diabetes is a matter of intensive investigation.
Nonetheless, it is well established that macrophages
are a major source of proinﬂammatory cytokines
proposed to contribute to the development of insulin
resistance as well as -cell destruction. In addition to
macrophages, other types of hematopoietic cells may
be important. It was recently shown that mast cells
accumulate in adipose tissue during obesity and that
genetic deﬁciency or pharmacological stabilization
of these cells protects mice from diet-induced obesity
and glucose intolerance (36). Obesity also modiﬁes
the population of adipose tissue resident T cells by
decreasing the number of TH2 and Treg cells and
increasing the number of CD8 T cells and TH1 T
Figure 1. JNK and IKK are key signal transduc-
ers implicated in the innate immune response.
During infection or tissue damage, pathogen-
associated molecular pattern (PAMP), damage-
associated molecular pattern (DAMP), and
proinﬂammatory cytokines are sensed by spe-
ciﬁc receptors that activate the proinﬂamma-
tory gene expression program. The kinases JNK
(A) and IKK (B) are activated by several
PAMP, DAMP, and cytokine receptors and play
a central role in transmitting these proinﬂam-
matory signals from the cell surface to transcrip-
tion factors involved in the control of the
expression of proinﬂammatory cytokines and
chemokines. TNF-, tumor necrosis factor ;
IL-1, interleukin-1 ; LPS, lipopolysaccharide;
HMG-B1, high mobility group box-1; Hsp60/
70, heat-shock proteins 60/70; ROS, reactive












cells, which cause macrophage recruitment and insu-
lin resistance (37–40).
Because in the obese state ATMs are localized
around necrotic adipocytes or their residual lipid
droplets (24), it appears likely that adipocyte necro-
sis is a key factor in adipose tissue inﬂammation. The
frequency of CLSs and necrotic adipocytes correlates
better with adipocyte size than adiposity per se. Both
necrotic adipocytes and CLSs are elevated in hor-
mone-sensitive lipase-knockout mice, a model of
adipocyte hypertrophy without increased adiposity
(24). Increased ATM numbers were also observed in
mice bearing a targeted mutation at the Ppar2 gene
crossed with ob/ob mice (POKO mice), a model of
limited adipose tissue expansion characterized by
adipocyte hypertrophy without overt obesity (41).
POKO mice display severe derangement in glucose
homeostasis caused by both insulin resistance and
loss of -cell function, which correlates with ectopic
deposition of toxic lipids and increased numbers of
CLSs in adipose tissue (41).
Morbidly obese patients that had undergone bari-
atric surgery, which decreases adipocyte size, exhib-
ited decreased CLS numbers within 3 mo, and the
remaining macrophages expressed the anti-inﬂam-
matory cytokine IL-10 (42). Moreover, weight-loss
surgery decreases the expression of the proinﬂamma-
tory genes MCP-1, CSF-3, HIF-1, and PLAUR in the
stromal-vascular fraction of white adipose tissue (42).
This observation is consistent with data from another
laboratory showing that bariatric surgery decreases
the circulating levels of the inﬂammatory markers
MCP-1, IL-6, CRP, and IL-18 (43). Therefore, the
chronic inﬂammatory process induced by obesity can be
resolved by weight loss, supporting the idea that the
presence of hypertrophic adipocytes is required to sustain
a state of chronic metabolic inﬂammation. Interestingly,
structures similar to CLSs were observed in fatty liver,
where dead fatty hepatocytes are enclosed by Kupffer cells
(44) (Fig. 2B), suggesting that “lipid-intoxicated” hepato-
cytes could play a role in steatohepatitis and Kupffer cell
activation. CLS morphology suggests an explanation for
the chronic nature of metabolic inﬂammation:
whereas acute inﬂammation is resolved as soon as the
causative factor disappears, in obesity new CLSs will
keep forming as soon as adipocytes become hyper-
trophic and then necrotic, ﬁnally leaving behind a
lipid droplet. Furthermore, when adipose tissue ex-
pansion approaches its limits, toxic lipids start to
accumulate in other tissues, such as the liver and
pancreatic islet (45–47), and circulating FFA concen-
trations increase. Finally, exposure to FFA leads to
activation of inﬂammatory signaling in several cell
types, including adipocytes (21, 48), hepatocytes (49,
50), myocytes (51), pancreatic islets (50), and mac-
rophages (21, 27, 28). Therefore, the critical factor
Figure 2. Obesity is characterized by adipocyte
hypertrophy, deposition of ectopic lipids, and
metabolic inﬂammation. A) MAC-2 staining
of adipose tissue from an obese mouse show-
ing a crown-like structure (CLS) comprising a
dead adipocyte surrounded by adipose tissue
macrophages (ATM). B) F4/80 staining of a
fatty liver from an obese mouse showing
Kupffer cells (brown F4/80 positive cells)
surrounding a large lipid vacuole from a fatty
hepatocyte. C) Obese adipose tissue is char-
acterized by production of proinﬂammatory
cytokines, hypertrophic adipocytes, alteration
of the resident T-cell population, mast cell
recruitment, and inﬁltration of M1 proin-
ﬂammatory macrophages to form CLSs.
Obese adipose tissue inﬁltrates other organs,
possibly changing the exposure of some nona-
dipose tissues to adipose tissue released fac-
tors from endocrine to paracrine. Lipid
deposition in nonadipose tissue further con-
tributes to metabolic stress, leading to loss of
glucose homeostasis and tissue damage. Fatty
liver also displays increased expression of
proinﬂammatory cytokines, and activated
Kupffer cells are probably a major source.
During obesity, macrophages inﬁltrate into
pancreatic islets and are probably contribut-
ing to the local production of proinﬂamma-
tory cytokines. It was reported that obesity is
associated with endoplasmic reticulum stress
in neurons leading to central leptin and insulin resistance, thereby further promoting obesity and loss of glucose
homeostasis. 1) Adipocyte. 2) TH2 T cell. 3) Treg (CD4
) T cell. 4) M2-polarized anti-inﬂammatory adipose tissue
macrophage. 5) Hepatocyte. 6) Kupffer cell. 7) Hypertrophyc adipocyte. 8) Fatty hepatocyte. 9) Effector (CD8) T cell.
10) TH1 (CD4
) T cell. 11) Mast cell. 12) M1-polarized proinﬂammatory adipose tissue macrophage. 13) Activated Kupffer











in metabolic inﬂammation is not adiposity per se but
an exhaustion of the lipid storage capacity of adipo-
cytes. This occurs in obesity and lipodistrophy, 2
conditions that are characterized by hypertrophic
adipocytes, adipocyte necrosis, ATM inﬁltration, CLS
formation, and ectopic accumulation of toxic proin-
ﬂammatory lipids. Hence, hypertrophic dysfunc-
tional adipocytes, ectopic deposition of toxic lipids,
and high circulating levels of FFA are the likely
causes of metabolic inﬂammation. Both of our sus-
pects, JNK1 and IKK, play a key role in transducing
signals generated at cytokine receptors, such as
TNF- and IL-1 receptors, to transcription factors
that control the expression of several proinﬂamma-
tory genes, including TNF- and IL-1 themselves.
Furthermore, JNK and IKK are also downstream of
pathways activated by toxic lipids and excessive glu-
cose levels.
METABOLIC STRESS PATHWAYS CONVERGE
ON JNK1 AND IKK
Obesity is characterized by alterations of the meta-
bolic milieu leading to insulin resistance and to a
cluster of obesity-associated diseases referred to as
the metabolic syndrome. We use the term “metabolic
stress” to indicate stress caused by perturbations in
the metabolic milieu. Metabolic stress can be de-
scribed as intracellular or extracellular depending on
whether the source of metabolic stress is exclusively
intracellular, such as intracellular accumulation of
toxic lipids, or extracellular, such as high levels of
circulating FFA or exceedingly high blood glucose.
Almost all the stressors and pathways proposed to
induce insulin resistance or -cell dysfunction result
in the activation of JNK or IKK or both, indepen-
dently of whether the signal is initiated at membrane
receptors that sense the extracellular milieu, or
whether it originates in response to intracellular
stress.
Circulating FFAs
Elevated plasma concentration of FFAs is a major
derangement of the extracellular milieu associated
with obesity. Administration of FFAs has been shown
to induce insulin resistance (52). Consistent with a
role of the innate immune system in insulin resis-
tance, several laboratories have shown that long-
chain saturated fatty acids (LCSFAs), and in particu-
lar palmitic acid (PA), can activate TLR2 and TLR4,
pattern recognition receptors that sense lipopetides
and lipopolysaccarides of bacterial walls (21, 51, 53).
Engagement of either TLR4 or TLR2 leads to recruit-
ment of the MyD88 adapter protein and formation of
signaling complexes containing the interleukin-1 re-
ceptor associated kinases (IRAKs) and the TNF re-
ceptor associated factor (TRAF) family members
TRAF3 and TRAF6. The latter leads to recruitment
and eventual activation of the MAP kinase kinase
kinase (MAP3K) TAK1, which is required for JNK
and IKK activation (54) (Fig. 3A). Peritoneal mac-
rophages bearing a targeted disruption at the Tlr4
gene (Tlr4/) show partially reduced JNK and IKK
activation in response to PA (21), suggesting the
existence of additional receptors. Another study
showed that isolated soleous muscles from mice with
a loss of function mutation at the Tlr4 locus (CH/HeJ
mutants) are protected from the negative effects of
PA on insulin signaling and insulin-induced glucose
uptake (55). A role for TLR4 signaling in FFA-
induced insulin resistance is supported by in vivo
experiments showing that Tlr4/ mice compared to
wild-type controls are protected from insulin resis-
tance induced by lipid infusion and, to a lesser
extent, from high-fat diet-induced insulin resistance
(21, 55, 56). Adoptive transfer experiments suggest that
the hematopoietic compartment is an important site of
the diabetogenic action of TLR4 signaling (57).
IL-1
IL-1 is induced during obesity, and it has been reported
that humans with detectable circulating IL-1 and in-
creased concentrations of blood IL-6 are more likely to
develop type 2 diabetes than individuals with high IL-6 but
undetectable IL-1 (58). Also, 3T3-L1 adipocytes exposed
to either IL-1 or IL-1 display defective insulin signaling
and insulin-stimulated glucose uptake (17, 59). Most
notably, interference with IL-1 receptor (IL-1R) signaling
using recombinant IL-1 receptor antagonist (IL-1Ra)
ameliorates glucose homeostasis in type 2 diabetes pa-
tients by improving pancreatic -cell function (60). Simi-
larly to TLR4, IL-1R activates JNK1 and IKK via the
MyD88 signaling pathway (Fig. 3B).
TNF-
TNF- expression is elevated in obese rodents and
humans, and treatment with TNF--neutralizing an-
tibodies improves insulin sensitivity in obese rats
(16). Similarly, mice bearing a targeted disruption of
the Tnf gene or of the genes encoding TNF-
receptors 1 and 2 (TNFR1, 2) are protected from
obesity-induced insulin resistance (15). TNF- tran-
siently activates both IKK and JNK1 through a
pathway different from the one used by IL-1R or
TLR2/4 (61). After binding of trimeric TNF-,
TNFR1 undergoes trimerization, and its death do-
main (DD), located on its intracellular portion,
forms a complex with the scaffolding kinase RIP1 and
the adaptor protein TRADD, which bind TRAF2 and
TRAF5 leading to IKK and JNK1 activation (Fig.
3C). RIP1 and TRAF2 recruit the IKK complex to
activated TNFR1, where the IKK subunit undergoes
phosphorylation and activation. JNK activation is also











the MAP3K MEKK1, leading to activation of the JNK
kinases MKK4 and MKK7 (61, 62).
Fas ligand (FasL)
FasL and its receptor Fas were proposed to play a role in
-cell death and dysfunction (63, 64). Fas is a member
of the TNFR superfamily, whose expression is con-
trolled by the IKK/NF-KB and JNK/AP-1 signaling, and
it activates JNK by a pathway dependent on the adapter
protein DAXX (65) (Fig. 3D).
Hyperglycemia and advanced glycated end products
(AGEs)
Hyperglycemia and AGEs have been proposed to contrib-
ute to insulin resistance (66–69) and -cell dysfunction
(70, 71). One mechanism by which hyperglycemia could
trigger insulin resistance is through consequent hyperin-
sulinemia (see below). Hyperglycemia also leads to non-
enzymatic reactions between glucose and amino groups
of proteins and other molecules, leading to the formation
of glycated proteins and AGEs, such as methylglyoxal
(72). AGEs are considered to play an important role in
diabetic complications (72); moreover, glycated albumin
was shown to induce defective insulin signaling in L6
myotubes (69). Although the role of JNK1 and IKK in
AGE-induced insulin resitance is not established, AGEs
activate both IKK and JNK1 via a speciﬁc AGE receptor
(RAGE) by a mechanism that remains to be identiﬁed
(73–75). RAGE is a pattern-recognition receptor that
recognizes a large family of compounds whose activation
promotes inﬂammation (76, 77). Mice bearing a tar-
geted deletion at the Rage gene are resistant to septic
shock, and the AGE-RAGE pathway was proposed to
Figure 3. Extracellular metabolic stress signaling leads to JNK and IKK activation. Obesity-caused derangements of the extracellular
milieu include hyperglycemia, increased levels of circulating FFAs, hyperinsulinemia, and increased levels of proinﬂammatory
cytokines. A) Extracellular FFAs activate JNK and IKK via Toll-like receptor (TLR) signaling pathway. B) Obesity is characterized by
elevation of the proinﬂammatory cytokine IL-1, whose receptor activates JNK and IKK using signaling modules common to the TLR
pathway. C) The proinﬂammatory cytokine TNF- is elevated in obesity and activates JNK and IKK by a speciﬁc signaling pathway.
D) Fas ligand (FasL), which was proposed to play a role in -cell dysfunction and death, activates JNK by a pathway involving the
adaptor protein Daxx. E) Chronic hyperinsulinemia was also implicated in JNK activation and different signaling pathways were
proposed. F) Hyperglycemia leads to increased levels of advanced-glycation end products (AGE), which activate JNK and IKK by











play a role in innate immunity by sensing molecules
generated at the site of tissue injury and promoting
inﬂammation (78, 79).
Insulin
Insulin has been reported to activate JNK in different
cell culture models by a phosphatidyl-inositide 3
kinase (PI3K)-dependent pathway, and it was pro-
posed that insulin-mediated JNK activation consti-
tutes a negative feedback loop in insulin signaling
(80). Two different mechanisms were proposed for
insulin-dependent JNK activation: one requires PI3K
activity and the Grb23Ras3MEK1/2 pathway (80),
whereas the second mechanism is independent of
PI3K activity but requires its adapter subunit p85 for
activation of JNK via Cdc42 and MKK4 (81) (Fig. 3E).
Intracellular glucotoxicity
The contribution of hyperglycemia to intracellular
metabolic stress depends on the cell type. This view is
supported by the fact that in type 1 diabetes, hyper-
glycemia-induced tissue damage is limited to a few
cell types, most notably neurons and endothelial cells
(82). A possible explanation could be that some cells,
such as smooth muscle cells, down-regulate glucose
uptake in the hyperglycemic environment to avoid
large ﬂuctuations in intracellular glucose concentra-
tions, whereas other cells, such as endothelial cells,
which are particularly sensitive to glucotoxicity, are
unable to efﬁciently down-regulate glucose uptake
and therefore develop intracellular hyperglycemia
(82, 83). A rise in intracellular glucose can activate
metabolic stress pathways, some of which have been
proposed to play a role in insulin resistance and islet
dysfunction. Consistent with this view, it was shown
that exposure to a hyperglycemic environment alone
is sufﬁcient to activate JNK in endothelial cells (84)
but not in hepatocytes (50).
Hexosamine pathway
The hexosamine pathway was also proposed as a
mechanism by which excessive intracellular glucose
concentrations could cause insulin resistance and
-cell dysfunction (85). Although the majority of
intracellular glucose is channeled into glycolysis to
form pyruvate, a small portion of fructose-6-phos-
phate is directed to the hexosamine pathway, which
involves conversion to glucosamine-6-phosphate by the
rate-limiting enzyme glutamine fructose-6-phosphate
amidotransferase (GFAT), to subsequently generate
uridindiphosphoglucose-n-acetylglucosamine (UDP-
Gl-N), a basic substrate for most protein glycosylation
pathways (85). Exposure to glucosamine has been
shown to trigger insulin resistance in adipocytes (86),
muscle cells (87), and in vivo (88). Furthermore,
GFAT overexpression impairs glucose-stimulated in-
sulin secretion in rat islets (89). Although the mech-
anism of glucosamine-induced insulin resistance re-
mains unclear, it was shown that glucosamine
induces endoplasmic reticulum stress (ER stress)
(90), NF-kB activity (90), and JNK activation (91)
(Fig. 4A).
Intracellular AGEs
AGEs accumulate intracellularly, but to date it is not
known whether intracellular AGEs play a direct role in
insulin resistance. However, it was proposed that mito-
chondrial reactive oxygen species (ROS) production pro-
motes the accumulation of intracellular AGEs and glu-
cosamine by inactivation of the enzyme glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and consequent
reduction of glucose catabolism by glycolysis (92). There-
fore, according to this model, mitochondrial ROS pro-
duction, the hexosamine pathway, and intracellular AGEs
might act as a cluster of stressors brought about by high
intracellular glucose concentrations (82, 92, 93) (Fig. 4A).
De novo lipogenesis (DNL)
DNL is the pathway by which glucose is converted
into lipids, a process occurring mostly in adipose
tissue and liver under physiological conditions. It was
proposed that tissues with a low lipogenic activity
under normal conditions, such as muscle and pan-
creatic islets, might undergo substantial DNL in
obese subjects, in response to hyperglycemia and
hyperinsulinemia. Therefore, hyperglycemia and hy-
perinsulinemia might also contribute to ectopic lipid
deposition and lipotoxicity during obesity (94) (Fig. 4A).
Intracellular lipids
Intracellular lipids were proposed to be a major
factor in the pathogenesis of insulin resistance and
pancreatic -cell dysfunction (45–47, 95, 96). Lipids
are normally stored in adipocytes, but chronic exces-
sive energy intake in the context of low-energy ex-
penditure leads to exceeding adipose tissue expan-
sion and ectopic lipid deposition. In cell culture
models, LCSFA exposure causes oxidative stress, ER
stress, insulin resistance, -cell dysfunction, and adi-
pocyte hypertrophy and induces cell death in several
cell types, including hepatocytes, muscle cells, adipo-
cytes, and  cells (48–51, 97–99). The mechanisms
for the deleterious effects of LCSFAs are only partially
understood. Exposure of cultured cells to LCSFAs, and in
particular PA, leads to changes in the composition of
cellular membranes, resulting in decreased mem-
brane ﬂuidity and morphological abnormalities of
mitochondria and ER (98–100). In addition to mem-
brane structural derangements, lipid metabolites
such as ceramides, diacylglycerol, lysophosphatidic
acid, and lysophosphatidylcholine may also be in-











(2, 101). JNK activation is believed to play an impor-
tant role in lipotoxicity. Long-chain saturated FFAs
trigger sustained JNK activation in different cell
types, and it was proposed that prolonged JNK acti-
vation causes insulin resistance, -cell dysfunction,
and cell death in these models (48–51). TLR4 and
TLR2 have been proposed to contribute to JNK and
IKK activation in response to circulating lipids by
sensing the extracellular meillieu (21, 51), but it is
unlikely that these membrane receptors are also the
major sensors of lipids accumulating intracellularly.
Thus, the major signaling pathway from intracellular
lipids to JNK activation remains to be identiﬁed. It
was suggested that, at least in some cells, PA activates
JNK by increasing the intracellular concentrations of
ceramides and diacylglycerol (DAG) causing sequen-
tial activation of protein kinase C (PKC), mixed
lineage kinase 4 (MLK4), and MAPK kinases MKK4
and MKK7, culminating in JNK activation (102).
Oxidative stress can also contribute to persistent JNK
activation through the inhibition of MAPK phospha-
tases (MPKs) (103). ER stress, which is induced by
LCSFAs but not by unsaturated FFAs (98), also can
cause JNK and IKK activation (104). Overall, several
signaling pathways are stimulated by intracellular
toxic lipids, including ER stress, ROS, and PKC,
which can all lead to JNK activation (Fig. 4B).
Importantly, interference with JNK activation or ac-
tivity is protective in different models of lipotoxicity
(28, 48–50, 101).
Oxidative stress
Oxidative stress was proposed as an important mech-
anism through which excessive intracellular glucose
Figure 4. Intracellular metabolic stress signaling cascades lead to JNK and
IKK activation. During obesity and diabetes, glucose and lipids can accumu-
late intracellularly, causing intracellular metabolic stress. A) Excessive intra-
cellular glucose was proposed to cause toxicity by multiple mechanisms:
generation of reactive oxygen species (ROS), production of glucosamine
(GlcN), intracellular AGEs, and secondary metabolites such as diacylglycerol
(DAG). Glucosamine was shown to cause ER stress, and DAG was proposed to
lead to JNK activation via PKC. ROS production was proposed to promote
glucosamine, AGE, and DAG formation via inhibition of GAPDH activity.
B) Excessive intracellular lipids were also proposed to cause cellular toxicity by
different mechanisms. Increased oxidation of FFAs may contribute to in-
creased production of ROS by the mitochondria, and intracellular FFAs cause
ER stress. Metabolites such as DAG, ceramides, and lysoposhpatydic acid
(LPA) were proposed to trigger JNK activation. A study suggests that saturated
FFA-mediated JNK activation depends on PKC-mediated activation of the
mixed lineage kinase MLK. C) Glucose and lipid oxidation leads to increased
ﬂux of electron through the electron transport chain. An overload of the
electron transport chain may lead to the production of ROS. ROS causes
sustained JNK activation by inactivating MAPK phosphatases (MKPs). The
MAPKKK ASK1 was also proposed to play a role in sustained JNK activation
induced by ROS. The role of ROS on IKK activation is not clear, and IKK was shown to increase the expression of the
antioxidant Mn-superoxyde dismutase (Mn-SOD) and ferritin heavy chain (FHC). D) Obesity causes ER stress in different
cell types. ER stress leads to JNK and IKK activation via IRE1-TRAF2 signaling. ER stress also leads to decreased protein
translation via PERK-dependent phosphorylation of elF2, which may synergize with IKK-mediated NF-kB activation by
reducing IkB translation rate. Efﬁcient ER stress-mediated JNK activation was reported to be dependent on the kinase











and lipids may impair glucose homeostasis. The
exaggerated ﬂux of glucose through glycolysis and
the Krebs cycle results in NADH and FADH produc-
tion that, when excessive, may overload the mito-
chondrial respiratory chain. Likewise, increased ﬂux
of lipids through -oxidation may also contribute to
an excessive electron ﬂow. In such scenarios oxygen
molecules could be converted to form superoxide
anion, which can then be converted to hydrogen
peroxide by superoxide dismutase (105–108). Super-
oxide and hydrogen peroxide react with other mol-
ecules in the cell to form different ROS (Fig. 4C).
Another mechanism by which intracellular hypergly-
cemia could induce ROS production is by increased
production of DAG, which can cause activation of
NADPH oxidase via PKC (109). Oxidative stress was
proposed to induce insulin resistance and pancreatic
-cell dysfunction, including reduced insulin produc-
tion, defective insulin secretion, and -cell death
(110, 111). In addition to JNK activation (103),
oxidative stress was proposed to activate NF-kB (112–
114). However, the link between NF-kB and ROS has
become complex because NF-kB activation has anti-
oxidant functions (103, 115, 116). JNK activation
may, however, promote ROS accumulation (117) and
link ROS production to insulin resistance and loss of
-cell function (118–120).
ER stress
Nutrient deprivation, changes in calcium concentra-
tion, accumulation of unfolded proteins, abnormal
post-translational modiﬁcations, and excessive eleva-
tion of intracellular lipids cause ER stress and trigger
signaling cascades that are initiated at the ER and
lead to activation of an adaptive response called the
unfolded protein response (UPR), whose goal is to
restore homeostasis (98, 99, 121–125). ER stress was
proposed to be a major factor in the pathogenesis of
obesity-induced insulin resistance (126), and it was
shown that synthetic chaperones, which dissolve pro-
tein aggregates, restore normal glycemia in obese
mice (127). ER stress leads to activation of JNK1 and
IKK signaling (104). The pathways from ER stress to
JNK1 and IKK are still being investigated; however,
inositol-requiring enzyme 1 (IRE1), a major sig-
naling molecule in UPR, was shown to link ER stress
to JNK and IKK activation (104). IRE1 forms a
complex with the adapter protein TRAF2, leading to
activation of apoptosis signal-regulating kinase 1
(ASK1) and consequent JNK1 activation (128) (Fig.
4D). It was reported that IKK forms a complex with
IRE1 via association with TRAF2 and that ER stress
activation of NF-kB is impaired in mouse embrionic
ﬁbroblasts lacking a functional IRE1 gene (129)
(Fig. 4D). Furthermore, it was shown that ER stress
and PA-mediated JNK activation are, at least in part,
dependent on the proinﬂammatory kinase PKR, al-
though the pathway linking PA and ER-stress to PKR
is not completely understood (130) (Fig. 4D).
Islet amyloid polypeptide (IAPP)
IAPP forms amyloid aggregates in islets of type 2
diabetes patients and was proposed to play a role in
-cell death and dysfunction. IAPP activates JNK1 in 
cells, and IAPP-induced cell death is inhibited by a JNK
inhibitor and JNK1 antisense olygonucleotides (131).
JNK1 AND IKK LINK METABOLIC STRESS TO
INSULIN RESISTANCE
JNK1 and IKK contribute to insulin resistance and
type 2 diabetes through multiple mechanisms.
Serine/threonine phosphorylation of insulin recep-
tor substrates 1 and 2 (IRS1-2) is believed to be an
important mediator of insulin resistance because it
results in uncoupling of insulin receptor activation
from downstream signaling (132–134). This hypoth-
esis is supported by a study showing that mice
expressing an IRS1 variant in which the serine phos-
phorylation sites Ser-302, Ser-307, and Ser-612 were
replaced by alanines (IRS1 Ser3Ala) are protected
from high-fat diet-induced insulin resistance (135).
By contrast, mice expressing an IRS1 variant with
only Ser-307 mutated to alanine are more susceptible
to developing insulin resistance when fed a high-fat
diet (136). Therefore, the inhibitory action of IRS1
serine/threonine phosphorylation on insulin signal-
ing could be independent from Ser-307 phosphory-
lation. IKK was reported to phosphorylate IRS1 on
multiple serine residues (137–139), but the contribu-
tion of direct IRS1 phosphorylation by IKK to
induction of insulin resistance is not clear because
IKK seems to exert its diabetogenic effects via
NF-kB activation in a cell type-speciﬁc manner (29,
140). For JNK1, however, there is a good correlation
between its activation and IRS1, IRS2 serine/
threonie phosphorylation (11, 50, 141–143), a corre-
lation that so far has not been observed for IKK.
Another mechanism by which JNK1 and IKK pro-
mote insulin resistance is by induction of proinﬂamma-
tory cytokines in different cell types, especially within
macrophages (28, 29). IKK overexpression in hepato-
cytes causes local and systemic induction of proinﬂam-
matory genes and systemic insulin resistance in the
absence of obesity (140). Interestingly, IKK-induced
insulin resistance is nearly fully reversed with neutral-
izing antibodies against IL-6 (140). Mice with a targeted
disruption of the Ikk gene in hepatocytes display
decreased liver expression of proinﬂammatory cyto-
kines and improved insulin-mediated suppression of
hepatic glucose production, but glucose uptake and
metabolism in other tissues remain unaffected (29). By
contrast, disruption of IKK in myeloid cells results in
a systemic improvement of insulin sensitivity in a model
of diet-induced insulin resistance (29). These results
strongly suggest that a major mechanism of IKK











production of proinﬂammatory cytokines by myeloid
cells, such as ATMs.
Induction of proinﬂammatory gene expression is
also an important mechanism in JNK1-promoted
insulin resistance. Jnk1/ mice show decreased ex-
pression of proinﬂammatory cytokines in models of
diet-induced insulin resistance (144), and a condi-
tional deletion of Jnk1 in adipocytes decreases IL-6
serum levels and improves hepatic insulin sensitivity
(145). However, the role of adipocytes as critical
sources for IL-6 remains to be established because it
was reported that the majority of IL-6 released by
human adipose tissue comes from cells other than
adipocytes (146). It was also reported that LCSFA
activate JNK in macrophages and induce IL-6, IL-1,
and TNF- expression in a JNK1-dependent manner
(27, 28). Furthermore, macrophages from Jnk1/
mice exposed to PA release less IL-6 and TNF- than
macrophages from WT mice (145). In addition,
conditioned medium of PA-exposed WT macro-
phages can induce insulin resistance in cultured
muscle cells, whereas conditioned medium from
Jnk1/ macrophages exposed to PA does not (28).
Nonetheless, it was reported that knockout of Jnk1 in
myeloid cells mediated by expession of Cre recombi-
nase under control of the Lysozyme-M (LysM) pro-
moter did not improve glucose homeostasis in obese
mice (145). However, it is well established that the
LysM promoter is not active in either Kupffer cells or
in lymphocytes (147). As Kupffer cells (resident liver
macrophages) are a major source for IL-6 in the liver
during obesity (140) and PA-mediated induction of
IL-6 gene expression in cultured Kupffer cells is
JNK1 dependent (28), it is possible that JNK1 pro-
motes insulin resistance by inducing expression of
proinﬂammatory cytokines within Kupffer cells and
perhaps other hematopoietic cells in which the LysM
promoter is inactive. Consistent with this view, mice
lacking Jnk1 in hematopoietic cells (including lym-
phoid and Kupffer cells), generated by adoptive
transfer, display decreased expression of proinﬂam-
matory cytokines during diet-induced obesity, and
deletion of JNK1 within hematopoietic cells is pro-
tective toward obesity-induced insulin resistance (27,
28). Furthermore, JNK1 activity in hematopoietic
cells is required for the transition from steatosis to
steatohepatitis in the choline deﬁciency model of
steatohepatitis (148). Altogether these studies show
that JNK1 activity in hematopoietic cells and in
adipocytes promotes metabolic inﬂammation during
obesity and steatosis at least in part through the
induction of inﬂammatory cytokines (Fig. 5A).
A ROLE FOR JNK1 AND IKK IN THE
DEVELOPMENT OF OBESITY
Both JNK1 and IKK exert substantial effects on the
development of adiposity, and in the case of IKK,
these effects were shown to depend on its activation
within the hypothalamus. Increased NF-kB activity
was observed in the hypothalamus of mice fed a
high-fat diet (HFD) (149). Lentivirus-mediated over-
expression of a dominant negative IKK mutant
in the mediobasal hypothalamus (MBH) protected
mice from HFD-induced obesity by decreasing food in-
take, whereas overexpression of a constitutively active
IKK mutant in the MBH promoted food intake and
weight gain (149). Congruently, mice bearing a condi-
tional Ikk gene disruption in the brain are resistant to
HFD-induced obesity and display decreased food intake
compared to controls (149). It was proposed that activa-
tion of the IKK3NF-kB axis in the hypothalamus pro-
motes food intake and obesity through induction of
SOCS3 gene expression, leading to inhibition of leptin
signaling via the JAK-STAT axis (149) (Fig. 5B). It was also
proposed that central activation of the IKK3NF-kB axis
in mice fed an HFD is in part due to ER stress (149) and
that ER stress is involved in central leptin and insulin
resistance (149, 150). To date it is not known how a
high-fat diet causes ER stress in the hypothalamus and
whether ER stress operates in synergy with other pathways.
Indeed, mice with a targeted disruption of the MyD88
gene in the central nervous system are protected from
diet-induced obesity and leptin resistance and display
reduced central IKK activation by HFD (151). Because
ER stress is also known to activate JNK, it was proposed
that hypothalamic activation of JNK1 could also favor
positive energy balance (152) (Fig. 5B). Jnk1-knockout
mice were found to be obesity resistant in both dietary
and genetic models (11). Total adiposity is decreased by
50% in Jnk1/ mice fed an HFD, with subcutaneous
and intraperitoneal adipose tissue depots affected to the
same extent (28).
The mechanism by which JNK1 affects energy
balance and/or lipid metabolism is still under inves-
tigation. This function has been mapped to a tissue
of nonhematopoietic origin involved in the control
of energy expenditure (28). Conditional Jnk1 gene
mutation studies suggest that JNK1 activity in neu-
rons but not in adipocytes, myocytes, hepatocytes, or
myeloid cells is required for efﬁcient HFD-induced
obesity (143, 145, 153, 154). It was also shown that
conditional Jnk1 gene deletion in neurons leads to
activation of the hypothalamic-pituitary-thyroid axis.
Indeed, mice lacking JNK1 in the nervous system
display increased expression of hypothalamic thyro-
tropin-releasing hormone (TRH) and pituitary thy-
roid-stimulating hormone (TSH). This enhanced
TRH and TSH expression was associated with in-
creased circulating levels of thyroid hormones (T3
and T4). Another study showed that JNK1 in neurons
is not required for HFD-induced leptin resistance
(151). Whether JNK1 plays a role in HFD-induced
neuronal insulin resistance is not known (Fig. 5B).
Comparison of mice bearing Jnk1 deletion in the
nonhematopoietic compartment to weight-matched
controls indicates that the improved glucose homeosta-
sis in Jnk1/ mice is partially due to their leaner











consistently show that JNK1 inactivation in neurons,
which causes a leaner phenotype, is sufﬁcient to im-
prove insulin and glucose tolerance in the HFD model,
whereas JNK1 inactivation in myeloid cells, adipocytes,
hepatocytes, or myocytes at best improved insulin tol-
erance but not glucose tolerance (143, 145, 153, 154).
Overall, these results suggest that the improved glucose
tolerance observed in JNK1 knockout mice is partly due
to their leaner phenotype.
JNK1 AND IKK IN OBESITY-INDUCED -CELL
FAILURE
Glucose homeostasis depends on the equilibrium
between insulin sensitivity and insulin production by
pancreatic  cells, and type 2 diabetes develops in
insulin-resistant subjects with insufﬁcient compensa-
tory insulin secretion (155). The  cells are particu-
larly sensitive to metabolic stress because they have
low antioxidant defenses (156) and are susceptible to
cytokine-induced cell death (157). Recent data
strongly suggest that targeting inﬂammation might
be an effective approach to improve the -cell com-
pensatory response in type 2 diabetes. Indeed, a
placebo-controlled double-blind clinical trial involv-
ing 70 type 2 diabetes patients showed that treatment
with IL-1 receptor antagonist (IL-1Ra) improves glu-
cose homeostasis by enhancing -cell function with
no observable side effects (60). This observation was
recapitulated in mice fed an HFD in which IL-1Ra
administration improved glucose homeostasis and
-cell survival and function (158). The fact that JNK1
and IKK are activated by IL-1R (Fig. 3B) makes
them candidate effectors for the deleterious effects
of IL-1 signaling on pancreatic islets. Indeed, it was
shown that transgenic mice expressing in  cells a
nondegradable form of the IKK substrate IkB,
known as IkB super repressor (IkB-SR), are pro-
tected from induction of diabetes by multiple low-
Figure 5. JNK and IKK activation promotes the derange-
ment of glucose homeostasis; different mechanisms may be
implicated. A) Increased JNK and IKK activities during
obesity promote insulin resistance. The proposed mecha-
nisms involve direct interference with insulin signaling in
insulin target cells by phosphorylation of serine/threonine
residues of IRS molecules and induction of the expression of
proinﬂammatory cytokines by the insulin target cells, macro-
phages, and other immune cells of hematopoietic origin. This
model implies that JNK and IKK activities lead to a feed-
forward loop causing further JNK and IKK activation. B) It
was proposed that obesity causes ER stress in brain centers,
leading to the activation of the IKK NF-kB signaling cascade
and increased expression of suppressor of cytokine signaling
3 (SOCS3), causing central insulin and leptin resistance,
which further promote obesity. JNK1 inactivation in neurons
leads to induction of the hypothalamic-pituitary-thyroid axis
possibly via induction of thyrotropin-releasing hormone
(TRH) expression in hypothalamic neurons. Although JNK is
unlikely to be implicated in leptin resitance it may play a role
in central insulin resistance. Furthermore, SOCS3 transcription is induced by IL-6, whose gene expression is controlled by JNK
and IKK in different systems. C) JNK and IKK were proposed to be involved in -cell dysfunction. Possible mechanisms may
involve induction of proinﬂammatory cytokines gene expression such as IL-1 in pancreatic -cells and in islet-associated
macrophages, and interference with insulin autocrine signal. IKK activation also leads to increased iNOS gene expression and
excessive NO production might be toxic for the  cell. We propose here that sustained JNK activation may also sensitize  cells











dose streptozotocin injections, a model characterized
by loss of -cell mass and function (159). Moreover
mouse islets expressing the IkB-SR transgene are
protected from the deleterious effects of IL-1 
INF- (159). Human islets infected with an adenovi-
rus expressing IkB-SR are also protected from the
effects of IL-1 on glucose-stimulated insulin secre-
tion and were more resistant to Fas-induced apopto-
sis (160). The mechanism by which the IKK-NF-kB
signaling pathway promotes -cell death and dysfunc-
tion, while promoting survival in most other cell
types, is not established. However, NF-kB also medi-
ates the induction of proinﬂammatory cytokines, Fas,
and inducible nitric oxyde synthase, all of which can
contribute to -cell cytotoxicity (Fig. 5C).
There is ample evidence that JNK is a major
mediator of islet dysfunction and death. Jnk1/
mice are protected from multiple low-dose STZ ad-
ministration (161), and JNK inhibition improves
glycemic control in mice after pancreatic islet trans-
plantation (162). Moreover, obese mice treated with
a speciﬁc JNK peptide inhibitor (DJNKi) showed
improved glucose tolerance and increased pancreatic
insulin mRNA and protein levels (163). We reported
that pancreatic islets from Jnk1/ mice or wild-type
islets treated with DJNKi are protected from inhibi-
tion of glucose-induced insulin gene expression by
PA (50). Others have observed that mouse islets
infected with an adenovirus expressing a dominant
negative JNK1 mutant are also protected from inhi-
bition of insulin gene expression by oxidative stress
(162). It was also shown that exposure of human
pancreatic islets to high glucose and leptin leads to
decreased insulin secretion and causes -cell death,
by a mechanism involving an autocrine IL-1 produc-
tion and JNK activity (164). The mechanism by which
JNK contributes to -cell dysfunction might involve
inhibition of autocrine insulin signaling (50) and
nuclear-cytoplasmic translocation of the transcrip-
tion factor PDX-1 (165), which are both required for
insulin gene expression. Although the downstream
mediators of JNK action in -cell death are not
known, we found that sustained JNK activation in-
duces degradation of the antiapoptotic protein c-
FLIPL in different cell types (166). c-FLIPL is a major
survival signal in  cells, required for protection from
TNF--induced -cell death (167). c-FLIPL also
switches high-glucose-induced Fas signaling from
apoptosis to cell proliferation (168). We therefore
speculate that during obesity sustained JNK activa-
tion within  cells could promote cell death at least
in part by inducing c-FLIPL degradation.
In obesity, macrophages inﬁltrate into pancreatic
islets, and because macrophages are a major source
of proinﬂammatory cytokines, it is plausible that
islet-associated macrophages play an important role
in -cell dysfunction and death (169). The role of
JNK1 and IKK in islet-associated macrophages was
not investigated, but it is likely to be similar to their
role in other macrophages where JNK1 and IKK are
implicated in the production of cytokines and other
inﬂammatory mediators (27–29).
CONCLUSIONS
Well before the discovery of insulin, it was known
that high doses of salicylates have beneﬁcial effects
on diabetic patients (13). The discovery that inter-
ference with TNF- signaling improves glucose ho-
meostasis in obese rodents demonstrated that inﬂam-
mation might be involved in obesity-induced glucose
intolerance (15, 16). Today, a large body of evidence
supports the view that metabolic inﬂammation is a
major cause of obesity-induced insulin resistance and
-cell dysfunction. A recent clinical trial showed that
the salicylate salsalate improves insulin sensitivity and
decreases inﬂammatory markers in obese nondia-
betic individuals (170), whereas another trial showed
that IL-1Ra decreases markers of inﬂammation and
ameliorates glycemic control by improving -cell
function in type 2 diabetes patients (60). These
studies demonstrate that speciﬁc anti-inﬂammatory
interventions in obese individuals and individuals
with type 2 diabetes may improve glycemic control,
insulin sensitivity, and -cell function.
The proinﬂammatory kinases JNK1 and IKK are
activated by almost all the signaling pathways pro-
posed to cause insulin resistance or -cell dysfunc-
tion, and their inhibition provides protection from
obesity and glucose intolerance in rodents (11, 12,
27–29, 144, 149, 162, 163). Interestingly JNK1 and
IKK are activated downstream from IL-1R (Fig. 3B),
and salicylate inhibits IKK activity and JNK activa-
tion at doses effective for its antidiabetogenic activity
(171, 172). Therefore, it is possible that reduced
JNK1 and IKK signaling may account for at least
part of the beneﬁcial effects of salsalate and IL-1Ra
observed in clinical trials. Furthermore, a mutation
on the gene expressing the JNK interacting protein-1
(JIP-1), causing reduced negative modulation on JNK
signaling, was shown to segregate with type 2 diabet-
ics (173). Taken together, the evidence strongly
suggests that JNK1 and IKK are candidate targets
for a new class of oral antidiabetogenic drugs target-
ing metabolic stress.
This review is supported by a Swiss National Science
Foundation grant SNF31003A-118172 to G.S. The authors
thank Barbara Becattini and Clive M. Brown for their critical
comments.
REFERENCES
1. Karin, M., Lawrence, T., and Nizet, V. (2006) Innate immunity
gone awry: linking microbial infections to chronic inﬂamma-
tion and cancer. Cell 124, 823–835
2. Schenk, S., Saberi, M., and Olefsky, J. M. (2008) Insulin












3. Hotamisligil, G. S. (2006) Inﬂammation and metabolic disor-
ders. Nature 444, 860–867
4. Weston, C. R., and Davis, R. J. (2007) The JNK signal transduc-
tion pathway. Curr. Opin. Cell Biol. 19, 142–149
5. Chang, L., and Karin, M. (2001) Mammalian MAP kinase
signalling cascades. Nature 410, 37–40
6. Chen, C. Y., Del Gatto-Konczak, F., Wu, Z., and Karin, M.
(1998) Stabilization of interleukin-2 mRNA by the c-Jun NH2-
terminal kinase pathway. Science 280, 1945–1949
7. Chen, C. Y., Gherzi, R., Andersen, J. S., Gaietta, G., Jurchott, K.,
Royer, H. D., Mann, M., and Karin, M. (2000) Nucleolin and
YB-1 are required for JNK-mediated interleukin-2 mRNA stabi-
lization during T-cell activation. Genes Dev. 14, 1236–1248
8. Hacker, H., and Karin, M. (2006) Regulation and function of
IKK and IKK-related kinases. Sci. STKE 2006, re13
9. Senftleben, U., and Karin, M. (2002) The IKK/NF-kappa B
pathway. Crit. Care Med. 30, S18–S26
10. Luo, J. L., Kamata, H., and Karin, M. (2005) IKK/NF-kappaB
signaling: balancing life and death: a new approach to cancer
therapy. J. Clin. Invest. 115, 2625–2632
11. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal,
K. T., Maeda, K., Karin, M., and Hotamisligil, G. S. (2002) A
central role for JNK in obesity and insulin resistance. Nature
420, 333–336
12. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W.,
Karin, M., and Shoelson, S. E. (2001) Reversal of obesity- and
diet-induced insulin resistance with salicylates or targeted
disruption of Ikkbeta. Science 293, 1673–1677
13. Williamson, R. (1901) On the treatment of glycosuria and
diabetes mellitus with sodium salicylate. Br. Med. J. 1, 760–762
14. Reid, J., Macdougall, A. I., and Andrews, M. M. (1957) Aspirin
and diabetes mellitus. Br. Med. J. 2, 1071–1074
15. Uysal, K. T., Wiesbrock, S. M., Marino, M. W., and Hotamisligil,
G. S. (1997) Protection from obesity-induced insulin resistance
in mice lacking TNF-alpha function. Nature 389, 610–614
16. Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M.
(1993) Adipose expression of tumor necrosis factor-alpha:
direct role in obesity-linked insulin resistance. Science 259,
87–91
17. Jager, J., Gremeaux, T., Cormont, M., Le Marchand-Brustel, Y.,
and Tanti, J. F. (2007) Interleukin-1beta-induced insulin resis-
tance in adipocytes through down-regulation of insulin recep-
tor substrate-1 expression. Endocrinology 148, 241–251
18. Klover, P. J., Clementi, A. H., and Mooney, R. A. (2005)
Interleukin-6 depletion selectively improves hepatic insulin
action in obesity. Endocrinology 146, 3417–3427
19. Pedersen, B. K., and Febbraio, M. A. (2007) Point: interleu-
kin-6 does have a beneﬁcial role in insulin sensitivity and
glucose homeostasis. J. Appl. Physiol. 102, 814–816
20. Pedersen, B. K., and Febbraio, M. A. (2008) Muscle as an
endocrine organ: focus on muscle-derived interleukin-6.
Physiol. Rev. 88, 1379–1406
21. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., and
Flier, J. S. (2006) TLR4 links innate immunity and fatty
acid-induced insulin resistance. J. Clin. Invest. 116, 3015–3025
22. Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J.,
Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., and Chen, H.
(2003) Chronic inﬂammation in fat plays a crucial role in the
development of obesity-related insulin resistance. J. Clin. Invest.
112, 1821–1830
23. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel,
R. L., and Ferrante, A. W., Jr. (2003) Obesity is associated with
macrophage accumulation in adipose tissue. J. Clin. Invest. 112,
1796–1808
24. Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E.,
Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., and Obin,
M. S. (2005) Adipocyte death deﬁnes macrophage localization
and function in adipose tissue of obese mice and humans. J.
Lipid Res. 46, 2347–2355
25. Lumeng, C. N., Bodzin, J. L., and Saltiel, A. R. (2007) Obesity
induces a phenotypic switch in adipose tissue macrophage
polarization. J. Clin. Invest. 117, 175–184
26. Lumeng, C. N., Deyoung, S. M., Bodzin, J. L., and Saltiel, A. R.
(2007) Increased inﬂammatory properties of adipose tissue
macrophages recruited during diet-induced obesity. Diabetes
56, 16–23
27. Vallerie, S. N., Furuhashi, M., Fucho, R., and Hotamisligil, G. S.
(2008) A predominant role for parenchymal c-Jun amino
terminal kinase (JNK) in the regulation of systemic insulin
sensitivity. PLoS ONE 3, e3151
28. Solinas, G., Vilcu, C., Neels, J. G., Bandyopadhyay, G. K., Luo,
J. L., Naugler, W., Grivennikov, S., Wynshaw-Boris, A., Scadeng,
M., Olefsky, J. M., and Karin, M. (2007) JNK1 in hematopoiet-
ically derived cells contributes to diet-induced inﬂammation
and insulin resistance without affecting obesity. Cell Metab. 6,
386–397
29. Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z. W.,
Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., and Karin,
M. (2005) IKK-beta links inﬂammation to obesity-induced
insulin resistance. Nat. Med. 11, 191–198
30. Furuhashi, M., Fucho, R., Gorgun, C. Z., Tuncman, G., Cao,
H., and Hotamisligil, G. S. (2008) Adipocyte/macrophage fatty
acid-binding proteins contribute to metabolic deterioration
through actions in both macrophages and adipocytes in mice.
J. Clin. Invest. 118, 2640–2650
31. Lesniewski, L. A., Hosch, S. E., Neels, J. G., de Luca, C.,
Pashmforoush, M., Lumeng, C. N., Chiang, S. H., Scadeng, M.,
Saltiel, A. R., and Olefsky, J. M. (2007) Bone marrow-speciﬁc
Cap gene deletion protects against high-fat diet-induced insu-
lin resistance. Nat. Med. 13, 455–462
32. Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel,
C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D.,
Brombacher, F., Ferrante, A. W., and Chawla, A. (2007) Macro-
phage-speciﬁc PPARgamma controls alternative activation and
improves insulin resistance. Nature 447, 1116–1120
33. Hevener, A. L., Olefsky, J. M., Reichart, D., Nguyen, M. T.,
Bandyopadyhay, G., Leung, H. Y., Watt, M. J., Benner, C.,
Febbraio, M. A., Nguyen, A. K., Folian, B., Subramaniam, S.,
Gonzalez, F. J., Glass, C. K., and Ricote, M. (2007) Macrophage
PPAR gamma is required for normal skeletal muscle and
hepatic insulin sensitivity and full antidiabetic effects of thia-
zolidinediones. J. Clin. Invest. 117, 1658–1669
34. Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K.,
Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K.,
and Kasuga, M. (2006) MCP-1 contributes to macrophage
inﬁltration into adipose tissue, insulin resistance, and hepatic
steatosis in obesity. J. Clin. Invest. 116, 1494–1505
35. Patsouris, D., Li, P. P., Thapar, D., Chapman, J., Olefsky, J. M.,
and Neels, J. G. (2008) Ablation of CD11c-positive cells nor-
malizes insulin sensitivity in obese insulin resistant animals. Cell
Metab. 8, 301–309
36. Liu, J., Divoux, A., Sun, J., Zhang, J., Clement, K., Glickman,
J. N., Sukhova, G. K., Wolters, P. J., Du, J., Gorgun, C. Z., Doria,
A., Libby, P., Blumberg, R. S., Kahn, B. B., Hotamisligil, G. S.,
and Shi, G. P. (2009) Genetic deﬁciency and pharmacological
stabilization of mast cells reduce diet-induced obesity and
diabetes in mice. Nat. Med. 15, 940–945
37. Lumeng, C. N., Maillard, I., and Saltiel, A. R. (2009) T-ing up
inﬂammation in fat. Nat. Med. 15, 846–847
38. Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H.,
Ohsugi, M., Otsu, M., Hara, K., Ueki, K., Sugiura, S., Yo-
shimura, K., Kadowaki, T., and Nagai, R. (2009) CD8 effector
T cells contribute to macrophage recruitment and adipose
tissue inﬂammation in obesity. Nat. Med. 15, 914–920
39. Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami,
J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F.,
Maezawa, Y., Drucker, D. J., Engleman, E., Winer, D., and
Dosch, H. M. (2009) Normalization of obesity-associated insu-
lin resistance through immunotherapy. Nat. Med. 15, 921–929
40. Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J.,
Nayer, A., Lee, J., Goldﬁne, A. B., Benoist, C., Shoelson, S., and
Mathis, D. (2009) Lean, but not obese, fat is enriched for a
unique population of regulatory T cells that affect metabolic
parameters. Nat. Med. 15, 930–939
41. Medina-Gomez, G., Gray, S. L., Yetukuri, L., Shimomura, K.,
Virtue, S., Campbell, M., Curtis, R. K., Jimenez-Linan, M.,
Blount, M., Yeo, G. S., Lopez, M., Seppanen-Laakso, T., Ash-
croft, F. M., Oresic, M., and Vidal-Puig, A. (2007) PPAR gamma
2 prevents lipotoxicity by controlling adipose tissue expand-
ability and peripheral lipid metabolism. PLoS Genet. 3, e64
42. Cancello, R., Henegar, C., Viguerie, N., Taleb, S., Poitou, C.,
Rouault, C., Coupaye, M., Pelloux, V., Hugol, D., Bouillot, J. L.,











G. S., Zucker, J. D., Basdevant, A., Langin, D., and Clement, K.
(2005) Reduction of macrophage inﬁltration and chemoattrac-
tant gene expression changes in white adipose tissue of mor-
bidly obese subjects after surgery-induced weight loss. Diabetes
54, 2277–2286
43. Schernthaner, G. H., Kopp, H. P., Kriwanek, S., Krzyzanowska,
K., Satler, M., Koppensteiner, R., and Schernthaner, G. (2006)
Effect of massive weight loss induced by bariatric surgery on
serum levels of interleukin-18 and monocyte-chemoattractant-
protein-1 in morbid obesity. Obes. Surg. 16, 709–715
44. Lefkowitch, J. H., Haythe, J. H., and Regent, N. (2002) Kupffer
cell aggregation and perivenular distribution in steatohepati-
tis. Mod. Pathol. 15, 699–704
45. Unger, R. H. (2003) Minireview: weapons of lean body mass
destruction: the role of ectopic lipids in the metabolic syn-
drome. Endocrinology 144, 5159–5165
46. Savage, D. B., Petersen, K. F., and Shulman, G. I. (2007)
Disordered lipid metabolism and the pathogenesis of insulin
resistance. Physiol. Rev. 87, 507–520
47. Virtue, S., and Vidal-Puig, A. (2008) It’s not how fat you are, it’s
what you do with it that counts. PLoS Biol. 6, e237
48. Nguyen, M. T., Satoh, H., Favelyukis, S., Babendure, J. L.,
Imamura, T., Sbodio, J. I., Zalevsky, J., Dahiyat, B. I., Chi,
N. W., and Olefsky, J. M. (2005) JNK and tumor necrosis
factor-alpha mediate free fatty acid-induced insulin resistance
in 3T3–L1 adipocytes. J. Biol. Chem. 280, 35361–35371
49. Malhi, H., Bronk, S. F., Werneburg, N. W., and Gores, G. J.
(2006) Free fatty acids induce JNK-dependent hepatocyte
lipoapoptosis. J. Biol. Chem. 281, 12093–12101
50. Solinas, G., Naugler, W., Galimi, F., Lee, M. S., and Karin, M.
(2006) Saturated fatty acids inhibit induction of insulin gene
transcription by JNK-mediated phosphorylation of insulin-
receptor substrates. Proc. Natl. Acad. Sci. U. S. A. 103, 16454–
16459
51. Senn, J. J. (2006) Toll-like receptor-2 is essential for the
development of palmitate-induced insulin resistance in myo-
tubes. J. Biol. Chem. 281, 26865–26875
52. Zheng, C., Xiang, J., Hunter, T., and Lin, A. (1999) The
JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun
kinase that stimulates c-Jun transcription activity. J. Biol. Chem.
274, 28966–28971
53. Nguyen, M. T., Favelyukis, S., Nguyen, A. K., Reichart, D.,
Scott, P. A., Jenn, A., Liu-Bryan, R., Glass, C. K., Neels, J. G.,
and Olefsky, J. M. (2007) A subpopulation of macrophages
inﬁltrates hypertrophic adipose tissue and is activated by free
fatty acids via Toll-like receptors 2 and 4 and JNK-dependent
pathways. J. Biol. Chem. 282, 35279–35292
54. Kawai, T., and Akira, S. (2007) TLR signaling. Semin. Immunol.
19, 24–32
55. Tsukumo, D. M., Carvalho-Filho, M. A., Carvalheira, J. B.,
Prada, P. O., Hirabara, S. M., Schenka, A. A., Araujo, E. P.,
Vassallo, J., Curi, R., Velloso, L. A., and Saad, M. J. (2007)
Loss-of-function mutation in Toll-like receptor 4 prevents
diet-induced obesity and insulin resistance. Diabetes 56, 1986–
1998
56. Poggi, M., Bastelica, D., Gual, P., Iglesias, M. A., Gremeaux, T.,
Knauf, C., Peiretti, F., Verdier, M., Juhan-Vague, I., Tanti, J. F.,
Burcelin, R., and Alessi, M. C. (2007) C3H/HeJ mice carrying
a toll-like receptor 4 mutation are protected against the
development of insulin resistance in white adipose tissue in
response to a high-fat diet. Diabetologia 50, 1267–1276
57. Saberi, M., Woods, N. B., de Luca, C., Schenk, S., Lu, J. C.,
Bandyopadhyay, G., Verma, I. M., and Olefsky, J. M. (2009)
Hematopoietic cell-speciﬁc deletion of toll-like receptor 4
ameliorates hepatic and adipose tissue insulin resistance in
high-fat-fed mice. Cell Metab. 10, 419–429
58. Spranger, J., Kroke, A., Mohlig, M., Hoffmann, K., Bergmann,
M. M., Ristow, M., Boeing, H., and Pfeiffer, A. F. (2003)
Inﬂammatory cytokines and the risk to develop type 2 diabetes:
results of the prospective population-based European Prospec-
tive Investigation into Cancer and Nutrition (EPIC)-Potsdam
Study. Diabetes 52, 812–817
59. He, J., Usui, I., Ishizuka, K., Kanatani, Y., Hiratani, K., Iwata,
M., Bukhari, A., Haruta, T., Sasaoka, T., and Kobayashi, M.
(2006) Interleukin-1alpha inhibits insulin signaling with phos-
phorylating insulin receptor substrate-1 on serine residues in
3T3–L1 adipocytes. Mol. Endocrinol. 20, 114–124
60. Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses,
J. A., Seifert, B., Mandrup-Poulsen, T., and Donath, M. Y.
(2007) Interleukin-1-receptor antagonist in type 2 diabetes
mellitus. N. Engl. J. Med. 356, 1517–1526
61. Liu, Z. G., Hsu, H., Goeddel, D. V., and Karin, M. (1996)
Dissection of TNF receptor 1 effector functions: JNK activation
is not linked to apoptosis while NF-kappaB activation prevents
cell death. Cell 87, 565–576
62. Matsuzawa, A., Tseng, P. H., Vallabhapurapu, S., Luo, J. L.,
Zhang, W., Wang, H., Vignali, D. A., Gallagher, E., and Karin,
M. (2008) Essential cytoplasmic translocation of a cytokine
receptor-assembled signaling complex. Science 321, 663–668
63. Schumann, D. M., Maedler, K., Franklin, I., Konrad, D.,
Storling, J., Boni-Schnetzler, M., Gjinovci, A., Kurrer, M. O.,
Gauthier, B. R., Bosco, D., Andres, A., Berney, T., Greter, M.,
Becher, B., Chervonsky, A. V., Halban, P. A., Mandrup-
Poulsen, T., Wollheim, C. B., and Donath, M. Y. (2007) The Fas
pathway is involved in pancreatic beta cell secretory function.
Proc. Natl. Acad. Sci. U. S. A. 104, 2861–2866
64. Maedler, K., Spinas, G. A., Lehmann, R., Sergeev, P., Weber,
M., Fontana, A., Kaiser, N., and Donath, M. Y. (2001) Glucose
induces beta-cell apoptosis via upregulation of the Fas receptor
in human islets. Diabetes 50, 1683–1690
65. Chang, H. Y., Nishitoh, H., Yang, X., Ichijo, H., and Balti-
more, D. (1998) Activation of apoptosis signal-regulating
kinase 1 (ASK1) by the adapter protein Daxx. Science 281,
1860–1863
66. Oku, A., Nawano, M., Ueta, K., Fujita, T., Umebayashi, I., Arakawa,
K., Kano-Ishihara, T., Saito, A., Anai, M., Funaki, M., Kikuchi, M.,
Oka, Y., and Asano, T. (2001) Inhibitory effect of hyperglycemia on
insulin-induced Akt/protein kinase B activation in skeletal muscle.
Am. J. Physiol. Endocrinol. Metab. 280, E816–E824
67. Nawano, M., Oku, A., Ueta, K., Umebayashi, I., Ishirahara, T.,
Arakawa, K., Saito, A., Anai, M., Kikuchi, M., and Asano, T.
(2000) Hyperglycemia contributes insulin resistance in hepatic
and adipose tissue but not skeletal muscle of ZDF rats. Am. J.
Physiol. Endocrinol. Metab. 278, E535–E543
68. Nawano, M., Ueta, K., Oku, A., Arakawa, K., Saito, A., Funaki,
M., Anai, M., Kikuchi, M., Oka, Y., and Asano, T. (1999)
Hyperglycemia impairs the insulin signaling step between PI
3-kinase and Akt/PKB activations in ZDF rat liver. Biochem.
Biophys. Res. Commun. 266, 252–256
69. Miele, C., Riboulet, A., Maitan, M. A., Oriente, F., Romano,
C., Formisano, P., Giudicelli, J., Beguinot, F., and Van
Obberghen, E. (2003) Human glycated albumin affects
glucose metabolism in L6 skeletal muscle cells by impairing
insulin-induced insulin receptor substrate (IRS) signaling
through a protein kinase C alpha-mediated mechanism.
J. Biol. Chem. 278, 47376–47387
70. Olson, L. K., Redmon, J. B., Towle, H. C., and Robertson, R. P.
(1993) Chronic exposure of HIT cells to high glucose concen-
trations paradoxically decreases insulin gene transcription and
alters binding of insulin gene regulatory protein. J. Clin. Invest.
92, 514–519
71. Robertson, R. P., Olson, L. K., and Zhang, H. J. (1994)
Differentiating glucose toxicity from glucose desensitization: a
new message from the insulin gene. Diabetes 43, 1085–1089
72. Goh, S. Y., and Cooper, M. E. (2008) Clinical review: the
role of advanced glycation end products in progression and
complications of diabetes. J. Clin. Endocrinol. Metab. 93,
1143–1152
73. Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C.,
Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., Hofmann, M. A.,
Kislinger, T., Ingram, M., Lu, A., Tanaka, H., Hori, O., Ogawa,
S., Stern, D. M., and Schmidt, A. M. (2000) Blockade of
RAGE-amphoterin signalling suppresses tumour growth and
metastases. Nature 405, 354–360
74. Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A.,
and Schmidt, A. M. (1997) Activation of the receptor for
advanced glycation end products triggers a p21(ras)-depen-
dent mitogen-activated protein kinase pathway regulated by
oxidant stress. J. Biol. Chem. 272, 17810–17814
75. Huttunen, H. J., Fages, C., and Rauvala, H. (1999) Receptor for
advanced glycation end products (RAGE)-mediated neurite
outgrowth and activation of NF-kappaB require the cytoplas-
mic domain of the receptor but different downstream signal-











76. Chavakis, T., Bierhaus, A., and Nawroth, P. P. (2004) RAGE
(receptor for advanced glycation end products): a central player
in the inﬂammatory response. Microbes Infect. 6, 1219–1225
77. Lin, L. (2006) RAGE on the Toll road? Cell. Mol. Immunol. 3,
351–358
78. Liliensiek, B., Weigand, M. A., Bierhaus, A., Nicklas, W.,
Kasper, M., Hofer, S., Plachky, J., Grone, H. J., Kurschus, F. C.,
Schmidt, A. M., Yan, S. D., Martin, E., Schleicher, E., Stern,
D. M., Hammerling, G. G., Nawroth, P. P., and Arnold, B.
(2004) Receptor for advanced glycation end products (RAGE)
regulates sepsis but not the adaptive immune response. J. Clin.
Invest. 113, 1641–1650
79. Bianchi, M. E. (2007) DAMPs, PAMPs and alarmins: all we
need to know about danger. J. Leukoc. Biol. 81, 1–5
80. Lee, Y. H., Giraud, J., Davis, R. J., and White, M. F. (2003) c-Jun
N-terminal kinase (JNK) mediates feedback inhibition of the
insulin signaling cascade. J. Biol. Chem. 278, 2896–2902
81. Taniguchi, C. M., Aleman, J. O., Ueki, K., Luo, J., Asano, T.,
Kaneto, H., Stephanopoulos, G., Cantley, L. C., and Kahn,
C. R. (2007) The p85alpha regulatory subunit of phosphoino-
sitide 3-kinase potentiates c-Jun N-terminal kinase-mediated
insulin resistance. Mol. Cell. Biol. 27, 2830–2840
82. Brownlee, M. (2005) The pathobiology of diabetic complica-
tions: a unifying mechanism. Diabetes 54, 1615–1625
83. King, G. L., and Loeken, M. R. (2004) Hyperglycemia-induced
oxidative stress in diabetic complications. Histochem. Cell. Biol.
122, 333–338
84. Ho, F. M., Liu, S. H., Liau, C. S., Huang, P. J., and Lin-Shiau, S. Y.
(2000) High glucose-induced apoptosis in human endothelial
cells is mediated by sequential activations of c-JunNH(2)-terminal
kinase and caspase-3. Circulation 101, 2618–2624
85. Rossetti, L. (2000) Perspective: hexosamines and nutrient
sensing. Endocrinology 141, 1922–1925
86. Marshall, S., Bacote, V., and Traxinger, R. R. (1991) Discovery
of a metabolic pathway mediating glucose-induced desensitiza-
tion of the glucose transport system: role of hexosamine
biosynthesis in the induction of insulin resistance. J. Biol. Chem.
266, 4706–4712
87. Ciaraldi, T. P., Carter, L., Nikoulina, S., Mudaliar, S., McClain,
D. A., and Henry, R. R. (1999) Glucosamine regulation of
glucose metabolism in cultured human skeletal muscle cells:
divergent effects on glucose transport/phosphorylation and
glycogen synthase in non-diabetic and type 2 diabetic subjects.
Endocrinology 140, 3971–3980
88. Veerababu, G., Tang, J., Hoffman, R. T., Daniels, M. C.,
Hebert, L. F., Jr., Crook, E. D., Cooksey, R. C., and McClain,
D. A. (2000) Overexpression of glutamine: fructose-6-phos-
phate amidotransferase in the liver of transgenic mice results
in enhanced glycogen storage, hyperlipidemia, obesity, and
impaired glucose tolerance. Diabetes 49, 2070–2078
89. Kaneto, H., Xu, G., Song, K. H., Suzuma, K., Bonner-Weir, S.,
Sharma, A., and Weir, G. C. (2001) Activation of the hex-
osamine pathway leads to deterioration of pancreatic beta-cell
function through the induction of oxidative stress. J. Biol.
Chem. 276, 31099–31104
90. Werstuck, G. H., Khan, M. I., Femia, G., Kim, A. J., Tedesco, V.,
Trigatti, B., and Shi, Y. (2006) Glucosamine-induced endoplasmic
reticulum dysfunction is associated with accelerated atherosclero-
sis in a hyperglycemic mouse model. Diabetes 55, 93–101
91. Andreozzi, F., D’Alessandris, C., Federici, M., Laratta, E., Del
Guerra, S., Del Prato, S., Marchetti, P., Lauro, R., Perticone, F.,
and Sesti, G. (2004) Activation of the hexosamine pathway
leads to phosphorylation of insulin receptor substrate-1 on
Ser307 and Ser612 and impairs the phosphatidylinositol 3-ki-
nase/Akt/mammalian target of rapamycin insulin biosynthetic
pathway in RIN pancreatic beta-cells. Endocrinology 145, 2845–
2857
92. Brownlee, M. (2001) Biochemistry and molecular cell biology
of diabetic complications. Nature 414, 813–820
93. Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S., Mat-
sumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J.,
Hammes, H. P., Giardino, I., and Brownlee, M. (2000) Nor-
malizing mitochondrial superoxide production blocks three
pathways of hyperglycaemic damage. Nature 404, 787–790
94. Dulloo, A. G., Gubler, M., Montani, J. P., Seydoux, J., and
Solinas, G. (2004) Substrate cycling between de novo lipogen-
esis and lipid oxidation: a thermogenic mechanism against
skeletal muscle lipotoxicity and glucolipotoxicity. Int. J. Obes.
Relat. Metab. Disord. 28(Suppl. 4), S29–S37
95. Unger, R. H., and Orci, L. (2001) Diseases of liporegulation:
new perspective on obesity and related disorders. FASEB J. 15,
312–321
96. Unger, R. H. (2002) Lipotoxic diseases. Annu. Rev. Med. 53,
319–336
97. Takahashi, K., Yamaguchi, S., Shimoyama, T., Seki, H.,
Miyokawa, K., Katsuta, H., Tanaka, T., Yoshimoto, K., Ohno,
H., Nagamatsu, S., and Ishida, H. (2008) JNK- and IkappaB-
dependent pathways regulate MCP-1 but not adiponectin
release from artiﬁcially hypertrophied 3T3–L1 adipocytes pre-
loaded with palmitate in vitro. Am. J. Physiol. Endocrinol. Metab.
294, E898–E909
98. Karaskov, E., Scott, C., Zhang, L., Teodoro, T., Ravazzola, M.,
and Volchuk, A. (2006) Chronic palmitate but not oleate
exposure induces endoplasmic reticulum stress, which may
contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology
147, 3398–3407
99. Borradaile, N. M., Han, X., Harp, J. D., Gale, S. E., Ory, D. S.,
and Schaffer, J. E. (2006) Disruption of endoplasmic reticulum
structure and integrity in lipotoxic cell death. J. Lipid Res. 47,
2726–2737
100. Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese,
R. V., Jr., Ory, D. S., and Schaffer, J. E. (2003) Triglyceride
accumulation protects against fatty acid-induced lipotoxicity.
Proc. Natl. Acad. Sci. U. S. A. 100, 3077–3082
101. Han, M. S., Park, S. Y., Shinzawa, K., Kim, S., Chung, K. W.,
Lee, J. H., Kwon, C. H., Lee, K. W., Park, C. K., Chung, W. J.,
Hwang, J. S., Yan, J. J., Song, D. K., Tsujimoto, Y., and Lee,
M. S. (2008) Lysophosphatidylcholine as a death effector in
the lipoapoptosis of hepatocytes. J. Lipid Res. 49, 84–97
102. Jaeschke, A., and Davis, R. J. (2007) Metabolic stress signaling
mediated by mixed-lineage kinases. Mol. Cell 27, 498–508
103. Kamata, H., Honda, S., Maeda, S., Chang, L., Hirata, H., and
Karin, M. (2005) Reactive oxygen species promote TNFalpha-
induced death and sustained JNK activation by inhibiting MAP
kinase phosphatases. Cell 120, 649–661
104. Zhang, K., and Kaufman, R. J. (2008) From endoplasmic-
reticulum stress to the inﬂammatory response. Nature 454,
455–462
105. Korshunov, S. S., Skulachev, V. P., and Starkov, A. A. (1997) High
protonic potential actuates a mechanism of production of reac-
tive oxygen species in mitochondria. FEBS Lett. 416, 15–18
106. Loschen, G., Flohe, L., and Chance, B. (1971) Respiratory
chain linked H(2)O(2) production in pigeon heart mitochon-
dria. FEBS Lett. 18, 261–264
107. Boveris, A., Oshino, N., and Chance, B. (1972) The cellular
production of hydrogen peroxide. Biochem. J. 128, 617–630
108. Boveris, A., and Chance, B. (1973) The mitochondrial gener-
ation of hydrogen peroxide: general properties and effect of
hyperbaric oxygen. Biochem. J. 134, 707–716
109. Inoguchi, T., Sonta, T., Tsubouchi, H., Etoh, T., Kakimoto, M.,
Sonoda, N., Sato, N., Sekiguchi, N., Kobayashi, K., Sumimoto,
H., Utsumi, H., and Nawata, H. (2003) Protein kinase C-
dependent increase in reactive oxygen species (ROS) produc-
tion in vascular tissues of diabetes: role of vascular NAD(P)H
oxidase. J. Am. Soc. Nephrol. 14, S227–S232
110. Eriksson, J. W. (2007) Metabolic stress in insulin’s target cells
leads to ROS accumulation: a hypothetical common pathway
causing insulin resistance. FEBS Lett. 581, 3734–3742
111. Kaneto, H., Katakami, N., Kawamori, D., Miyatsuka, T., Saka-
moto, K., Matsuoka, T. A., Matsuhisa, M., and Yamasaki, Y.
(2007) Involvement of oxidative stress in the pathogenesis of
diabetes. Antioxid. Redox Signal. 9, 355–366
112. Manna, S. K., Zhang, H. J., Yan, T., Oberley, L. W., and
Aggarwal, B. B. (1998) Overexpression of manganese super-
oxide dismutase suppresses tumor necrosis factor-induced
apoptosis and activation of nuclear transcription factor-
kappaB and activated protein-1. J. Biol. Chem. 273, 13245–
13254
113. Sen, C. K., and Packer, L. (1996) Antioxidant and redox
regulation of gene transcription. FASEB J. 10, 709–720
114. Schreck, R., Rieber, P., and Baeuerle, P. A. (1991) Reactive
oxygen intermediates as apparently widely used messengers in
the activation of the NF-kappa B transcription factor and











115. Li, N., and Karin, M. (1999) Is NF-kappaB the sensor of
oxidative stress? FASEB J. 13, 1137–1143
116. Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J.,
Alvarez, K., Jayawardena, S., De Smaele, E., Cong, R., Beau-
mont, C., Torti, F. M., Torti, S. V., and Franzoso, G. (2004)
Ferritin heavy chain upregulation by NF-kappaB inhibits
TNFalpha-induced apoptosis by suppressing reactive oxygen
species. Cell 119, 529–542
117. Ventura, J. J., Cogswell, P., Flavell, R. A., Baldwin, A. S., Jr., and
Davis, R. J. (2004) JNK potentiates TNF-stimulated necrosis by
increasing the production of cytotoxic reactive oxygen species.
Genes Dev. 18, 2905–2915
118. Temkin, V., and Karin, M. (2007) From death receptor to
reactive oxygen species and c-Jun N-terminal protein kinase:
the receptor-interacting protein 1 odyssey. Immunol. Rev. 220,
8–21
119. Matsuzawa, A., and Ichijo, H. (2008) Redox control of cell
fate by MAP kinase: physiological roles of ASK1-MAP kinase
pathway in stress signaling. Biochim. Biophys. Acta 1780,
1325–1336
120. Kaneto, H., Matsuoka, T. A., Katakami, N., Kawamori, D.,
Miyatsuka, T., Yoshiuchi, K., Yasuda, T., Sakamoto, K., Ya-
masaki, Y., and Matsuhisa, M. (2007) Oxidative stress and the
JNK pathway are involved in the development of type 1 and
type 2 diabetes. Curr. Mol. Med. 7, 674–686
121. Diakogiannaki, E., Welters, H. J., and Morgan, N. G. (2008)
Differential regulation of the endoplasmic reticulum stress
response in pancreatic beta-cells exposed to long-chain satu-
rated and monounsaturated fatty acids. J. Endocrinol. 197,
553–563
122. Diakogiannaki, E., and Morgan, N. G. (2008) Differential
regulation of the ER stress response by long-chain fatty acids in
the pancreatic beta-cell. Biochem. Soc. Trans. 36, 959–962
123. Guo, W., Wong, S., Xie, W., Lei, T., and Luo, Z. (2007)
Palmitate modulates intracellular signaling, induces endoplas-
mic reticulum stress, and causes apoptosis in mouse 3T3–L1
and rat primary preadipocytes. Am. J. Physiol. Endocrinol. Metab.
293, E576–E586
124. Wei, Y., Wang, D., Topczewski, F., and Pagliassotti, M. J. (2006)
Saturated fatty acids induce endoplasmic reticulum stress and
apoptosis independently of ceramide in liver cells. Am. J.
Physiol. Endocrinol. Metab. 291, E275–E281
125. Wu, J., and Kaufman, R. J. (2006) From acute ER stress to
physiological roles of the unfolded protein response. Cell Death
Differ. 13, 374–384
126. Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N.,
Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H., and
Hotamisligil, G. S. (2004) Endoplasmic reticulum stress links
obesity, insulin action, and type 2 diabetes. Science 306, 457–461
127. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt,
E., Smith, R. O., Gorgun, C. Z., and Hotamisligil, G. S. (2006)
Chemical chaperones reduce ER stress and restore glucose
homeostasis in a mouse model of type 2 diabetes. Science 313,
1137–1140
128. Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P.,
Harding, H. P., and Ron, D. (2000) Coupling of stress in the
ER to activation of JNK protein kinases by transmembrane
protein kinase IRE1. Science 287, 664–666
129. Hu, P., Han, Z., Couvillon, A. D., Kaufman, R. J., and Exton,
J. H. (2006) Autocrine tumor necrosis factor alpha links
endoplasmic reticulum stress to the membrane death receptor
pathway through IRE1alpha-mediated NF-kappaB activation
and down-regulation of TRAF2 expression. Mol. Cell. Biol. 26,
3071–3084
130. Nakamura, T., Furuhashi, M., Li, P., Cao, H., Tuncman, G.,
Sonenberg, N., Gorgun, C. Z., and Hotamisligil, G. S. (2010)
Double-stranded RNA-dependent protein kinase links patho-
gen sensing with stress and metabolic homeostasis. Cell 140,
338–348
131. Zhang, S., Liu, J., Dragunow, M., and Cooper, G. J. (2003)
Fibrillogenic amylin evokes islet beta-cell apoptosis through
linked activation of a caspase cascade and JNK1. J. Biol. Chem.
278, 52810–52819
132. Tanti, J. F., Gremeaux, T., van Obberghen, E., and Le March-
and-Brustel, Y. (1994) Serine/threonine phosphorylation of
insulin receptor substrate 1 modulates insulin receptor signal-
ing. J. Biol. Chem. 269, 6051–6057
133. White, M. F. (2003) Insulin signaling in health and disease.
Science 302, 1710–1711
134. Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson,
S. E., and White, M. F. (2002) Phosphorylation of Ser307 in
insulin receptor substrate-1 blocks interactions with the insulin
receptor and inhibits insulin action. J. Biol. Chem. 277, 1531–
1537
135. Morino, K., Neschen, S., Bilz, S., Sono, S., Tsirigotis, D.,
Reznick, R. M., Moore, I., Nagai, Y., Samuel, V., Sebastian, D.,
White, M., Philbrick, W., and Shulman, G. I. (2008) Muscle-
speciﬁc IRS-1 Ser-Ala transgenic mice are protected from
fat-induced insulin resistance in skeletal muscle. Diabetes 57,
2644–2651
136. Copps, K. D., Hancer, N. J., Opare-Ado, L., Qiu, W., Walsh, C.,
and White, M. F. (2010) Irs1 serine 307 promotes insulin
sensitivity in mice. Cell Metab. 11, 84–92
137. Gao, Z., Hwang, D., Bataille, F., Lefevre, M., York, D., Quon,
M. J., and Ye, J. (2002) Serine phosphorylation of insulin
receptor substrate 1 by inhibitor kappa B kinase complex.
J. Biol. Chem. 277, 48115–48121
138. Gao, Z., Zuberi, A., Quon, M. J., Dong, Z., and Ye, J. (2003)
Aspirin inhibits serine phosphorylation of insulin receptor
substrate 1 in tumor necrosis factor-treated cells through
targeting multiple serine kinases. J. Biol. Chem. 278, 24944–
24950
139. Herschkovitz, A., Liu, Y. F., Ilan, E., Ronen, D., Boura-Halfon,
S., and Zick, Y. (2007) Common inhibitory serine sites phos-
phorylated by IRS-1 kinases, triggered by insulin and inducers
of insulin resistance. J. Biol. Chem. 282, 18018–18027
140. Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L.,
Lee, J., and Shoelson, S. E. (2005) Local and systemic insulin
resistance resulting from hepatic activation of IKK-beta and
NF-kappaB. Nat. Med. 11, 183–190
141. Aguirre, V., Uchida, T., Yenush, L., Davis, R., and White,
M. F. (2000) The c-Jun NH(2)-terminal kinase promotes
insulin resistance during association with insulin receptor
substrate-1 and phosphorylation of Ser(307). J. Biol. Chem.
275, 9047–9054
142. Sharﬁ, H., and Eldar-Finkelman, H. (2008) Sequential phos-
phorylation of insulin receptor substrate-2 by glycogen syn-
thase kinase-3 and c-Jun NH2-terminal kinase plays a role in
hepatic insulin signaling. Am. J. Physiol. Endocrinol. Metab. 294,
E307–E315
143. Sabio, G., Kennedy, N. J., Cavanagh-Kyros, J., Jung, D. Y., Ko,
H. J., Ong, H., Barrett, T., Kim, J. K., and Davis, R. J. (2010)
Role of muscle JNK1 in obesity-induced insulin resistance. Mol.
Cell. Biol. 30, 106–115
144. Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M.,
and Hotamisligil, G. S. (2006) Functional in vivo interactions
between JNK1 and JNK2 isoforms in obesity and insulin
resistance. Proc. Natl. Acad. Sci. U. S. A. 103, 10741–10746
145. Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J.,
Barrett, T., Kim, J. K., and Davis, R. J. (2008) A stress signaling
pathway in adipose tissue regulates hepatic insulin resistance.
Science 322, 1539–1543
146. Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P., and
Bahouth, S. W. (2004) Comparison of the release of adipo-
kines by adipose tissue, adipose tissue matrix, and adipocytes
from visceral and subcutaneous abdominal adipose tissues of
obese humans. Endocrinology 145, 2273–2282
147. Maeda, S., Kamata, H., Luo, J. L., Leffert, H., and Karin, M.
(2005) IKKbeta couples hepatocyte death to cytokine-driven
compensatory proliferation that promotes chemical hepatocar-
cinogenesis. Cell 121, 977–990
148. Kodama, Y., Kisseleva, T., Iwaisako, K., Miura, K., Taura, K., De
Minicis, S., Osterreicher, C. H., Schnabl, B., Seki, E., and Brenner,
D. A. (2009) c-Jun N-terminal kinase-1 from hematopoietic cells
mediates progression from hepatic steatosis to steatohepatitis and
ﬁbrosis in mice. Gastroenterology 137, 1467–1477
149. Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., and Cai,
D. (2008) Hypothalamic IKKbeta/NF-kappaB and ER stress
link overnutrition to energy imbalance and obesity. Cell 135,
61–73
150. Ozcan, L., Ergin, A. S., Lu, A., Chung, J., Sarkar, S., Nie, D.,
Myers, M. G., Jr., and Ozcan, U. (2009) Endoplasmic reticulum
stress plays a central role in development of leptin resistance.











151. Kleinridders, A., Schenten, D., Konner, A. C., Belgardt, B. F.,
Mauer, J., Okamura, T., Wunderlich, F. T., Medzhitov, R., and
Bruning, J. C. (2009) MyD88 signaling in the CNS is required
for development of fatty acid-induced leptin resistance and
diet-induced obesity. Cell Metab. 10, 249–259
152. Yang, L., and Hotamisligil, G. S. (2008) Stressing the brain,
fattening the body. Cell 135, 20–22
153. Sabio, G., Cavanagh-Kyros, J., Barrett, T., Jung, D. Y., Ko, H. J.,
Ong, H., Morel, C., Mora, A., Reilly, J., Kim, J. K., and Davis,
R. J. (2010) Role of the hypothalamic-pituitary-thyroid axis in
metabolic regulation by JNK1. Genes Dev. 24, 256–264
154. Sabio, G., Cavanagh-Kyros, J., Ko, H. J., Jung, D. Y., Gray, S.,
Jun, J. Y., Barrett, T., Mora, A., Kim, J. K., and Davis, R. J.
(2009) Prevention of steatosis by hepatic JNK1. Cell Metab. 10,
491–498
155. Prentki, M., and Nolan, C. J. (2006) Islet beta cell failure in
type 2 diabetes. J. Clin. Invest. 116, 1802–1812
156. Tiedge, M., Lortz, S., Drinkgern, J., and Lenzen, S. (1997)
Relation between antioxidant enzyme gene expression and
antioxidative defense status of insulin-producing cells. Diabetes
46, 1733–1742
157. Kim, K. A., and Lee, M. S. (2009) Recent progress in research
on beta-cell apoptosis by cytokines. Front. Biosci. 14, 657–664
158. Sauter, N. S., Schulthess, F. T., Galasso, R., Castellani, L. W.,
and Maedler, K. (2008) The antiinﬂammatory cytokine inter-
leukin-1 receptor antagonist protects from high-fat diet-in-
duced hyperglycemia. Endocrinology 149, 2208–2218
159. Eldor, R., Yeffet, A., Baum, K., Doviner, V., Amar, D., Ben-
Neriah, Y., Christofori, G., Peled, A., Carel, J. C., Boitard, C.,
Klein, T., Serup, P., Eizirik, D. L., and Melloul, D. (2006)
Conditional and speciﬁc NF-kappaB blockade protects pancre-
atic beta cells from diabetogenic agents. Proc. Natl. Acad. Sci.
U. S. A. 103, 5072–5077
160. Giannoukakis, N., Rudert, W. A., Trucco, M., and Robbins,
P. D. (2000) Protection of human islets from the effects of
interleukin-1beta by adenoviral gene transfer of an Ikappa B
repressor. J. Biol. Chem. 275, 36509–36513
161. Fukuda, K., Tesch, G. H., and Nikolic-Paterson, D. J. (2008)
c-Jun amino terminal kinase 1 deﬁcient mice are protected
from streptozotocin-induced islet injury. Biochem. Biophys. Res.
Commun. 366, 710–716
162. Kaneto, H., Xu, G., Fujii, N., Kim, S., Bonner-Weir, S., and
Weir, G. C. (2002) Involvement of c-Jun N-terminal kinase in
oxidative stress-mediated suppression of insulin gene expres-
sion. J. Biol. Chem. 277, 30010–30018
163. Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka,
T. A., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y., and
Hori, M. (2004) Possible novel therapy for diabetes with cell-
permeable JNK-inhibitory peptide. Nat. Med. 10, 1128–1132
164. Maedler, K., Schulthess, F. T., Bielman, C., Berney, T., Bonny,
C., Prentki, M., Donath, M. Y., and Roduit, R. (2008) Glucose
and leptin induce apoptosis in human beta-cells and impair
glucose-stimulated insulin secretion through activation of c-
Jun N-terminal kinases. FASEB J. 22, 1905–1913
165. Kawamori, D., Kajimoto, Y., Kaneto, H., Umayahara, Y., Fujitani,
Y., Miyatsuka, T., Watada, H., Leibiger, I. B., Yamasaki, Y., and
Hori, M. (2003) Oxidative stress induces nucleo-cytoplasmic
translocation of pancreatic transcription factor PDX-1 through
activation of c-Jun NH(2)-terminal kinase. Diabetes 52, 2896–2904
166. Chang, L., Kamata, H., Solinas, G., Luo, J. L., Maeda, S.,
Venuprasad, K., Liu, Y. C., and Karin, M. (2006) The E3
ubiquitin ligase itch couples JNK activation to TNFalpha-
induced cell death by inducing c-FLIP(L) turnover. Cell 124,
601–613
167. Cottet, S., Dupraz, P., Hamburger, F., Dolci, W., Jaquet, M.,
and Thorens, B. (2002) cFLIP protein prevents tumor
necrosis factor-alpha-mediated induction of caspase-8-de-
pendent apoptosis in insulin-secreting betaTc-Tet cells. Di-
abetes 51, 1805–1814
168. Maedler, K., Fontana, A., Ris, F., Sergeev, P., Toso, C., Ober-
holzer, J., Lehmann, R., Bachmann, F., Tasinato, A., Spinas,
G. A., Halban, P. A., and Donath, M. Y. (2002) FLIP switches
Fas-mediated glucose signaling in human pancreatic beta cells
from apoptosis to cell replication. Proc. Natl. Acad. Sci. U. S. A.
99, 8236–8241
169. Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A.,
Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider,
M. K., Biollaz, G., Fontana, A., Reinecke, M., Homo-Delarche,
F., and Donath, M. Y. (2007) Increased number of islet-
associated macrophages in type 2 diabetes. Diabetes 56, 2356–
2370
170. Fleischman, A., Shoelson, S. E., Bernier, R., and Goldﬁne, A. B.
(2008) Salsalate improves glycemia and inﬂammatory param-
eters in obese young adults. Diabetes Care 31, 289–294
171. Jiang, G., Dallas-Yang, Q., Liu, F., Moller, D. E., and Zhang,
B. B. (2003) Salicylic acid reverses phorbol 12-myristate-13-
acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-
induced insulin receptor substrate 1 (IRS1) serine 307
phosphorylation and insulin resistance in human embryonic
kidney 293 (HEK293) cells. J. Biol. Chem. 278, 180–186
172. Yin, M. J., Yamamoto, Y., and Gaynor, R. B. (1998) The
anti-inﬂammatory agents aspirin and salicylate inhibit the
activity of I(kappa)B kinase-beta. Nature 396, 77–80
173. Waeber, G., Delplanque, J., Bonny, C., Mooser, V., Steinmann,
M., Widmann, C., Maillard, A., Miklossy, J., Dina, C., Hani,
E. H., Vionnet, N., Nicod, P., Boutin, P., and Froguel, P. (2000)
The gene MAPK8IP1, encoding islet-brain-1, is a candidate for
type 2 diabetes. Nat. Genet. 24, 291–295
ht
tp
://
do
c.
re
ro
.c
h
16
